
Annual report 2022
added 12-23-2023
HEXO Corp. EPS Ratio 2011-2025 | HEXO
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio HEXO Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -0.89 | -1.77 | -0.38 | -0.17 | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.17 | -1.77 | -0.802 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Drug manufacturers industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Canopy Growth Corporation
CGC
|
-5.56 | $ 1.68 | -3.44 % | $ 181 M | ||
|
Alimera Sciences
ALIM
|
-0.84 | - | - | $ 142 M | ||
|
Assertio Holdings
ASRT
|
-4.67 | $ 0.74 | -3.53 % | $ 52.6 M | ||
|
Aerie Pharmaceuticals
AERI
|
-1.61 | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-0.5 | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-0.18 | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
-6.71 | - | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
-4.1 | $ 5.1 | -5.59 % | $ 86.3 M | ||
|
Catalent
CTLT
|
-5.76 | - | - | $ 11.5 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-9.66 | - | -0.1 % | $ 2.03 B | ||
|
DURECT Corporation
DRRX
|
-1.05 | - | - | $ 50.1 M | ||
|
Organogenesis Holdings
ORGO
|
-0.01 | $ 4.76 | -1.14 % | $ 627 M | ||
|
Eagle Pharmaceuticals
EGRX
|
2.76 | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-10.4 | - | - | $ 28.9 M | ||
|
Pacira BioSciences
PCRX
|
-2.15 | $ 26.64 | 1.33 % | $ 1.23 B | ||
|
Emergent BioSolutions
EBS
|
-14.8 | $ 12.27 | 7.44 % | $ 628 M | ||
|
Evoke Pharma
EVOK
|
-2.33 | $ 10.97 | 0.14 % | $ 36.7 M | ||
|
Athenex
ATNX
|
-15.8 | - | -23.39 % | $ 1.76 M | ||
|
Rockwell Medical
RMTI
|
-0.37 | $ 0.88 | -5.2 % | $ 20.5 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-0.51 | $ 21.43 | 0.3 % | $ 2.04 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
-2.79 | $ 3.52 | -2.07 % | $ 4.37 M | ||
|
Evolus
EOLS
|
-0.81 | $ 7.14 | 1.42 % | $ 443 M | ||
|
Harrow Health
HROW
|
-0.75 | $ 46.39 | -1.43 % | $ 1.51 B | ||
|
China Pharma Holdings
CPHI
|
-0.27 | $ 1.53 | -1.92 % | $ 26.7 M | ||
|
Bausch Health Companies
BHC
|
-1.62 | $ 6.87 | -0.79 % | $ 2.51 B | ||
|
Veru
VERU
|
-0.28 | $ 2.39 | -1.24 % | $ 322 M | ||
|
Lannett Company
LCI
|
-5.74 | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
-0.51 | $ 1.81 | -5.99 % | $ 402 M | ||
|
cbdMD
YCBD
|
-1.79 | $ 1.18 | -3.28 % | $ 5.09 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-0.14 | $ 3.04 | 20.16 % | $ 42.7 M | ||
|
Neoleukin Therapeutics
NLTX
|
27.8 | - | - | $ 193 M | ||
|
Solid Biosciences
SLDB
|
-3.06 | $ 5.77 | -1.79 % | $ 236 M | ||
|
PetIQ
PETQ
|
0.07 | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
-3.28 | $ 4.34 | 6.9 % | $ 131 M | ||
|
Jupiter Wellness
JUPW
|
-0.91 | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
-1.25 | $ 12.77 | -2.85 % | $ 1.75 B | ||
|
ProPhase Labs
PRPH
|
1.17 | $ 0.12 | 0.87 % | $ 1.9 M | ||
|
Radius Health
RDUS
|
-1.49 | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
-0.14 | - | -4.76 % | $ 65.3 M | ||
|
Sundial Growers
SNDL
|
-1.1 | $ 1.96 | -11.31 % | $ 3.37 M | ||
|
OptiNose
OPTN
|
-0.32 | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
-2.06 | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
1.4 | $ 0.64 | -0.91 % | $ 30.6 M | ||
|
Tricida
TCDA
|
-3.44 | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
-2.35 | $ 11.19 | -7.9 % | $ 6.92 B | ||
|
TherapeuticsMD
TXMD
|
-0.98 | $ 1.7 | -2.86 % | $ 17.7 M | ||
|
Zomedica Corp.
ZOM
|
-0.035 | - | -0.21 % | $ 98 M | ||
|
Viatris
VTRS
|
1.71 | $ 11.65 | - | $ 14.1 B |